What Is Fertility Treatment and How Does It Work?

Fertility treatment is a broad category of medical interventions designed to help people conceive when pregnancy does not happen on its own. It ranges from straightforward steps like taking a pill that triggers ovulation all the way to complex laboratory procedures where eggs and sperm are combined outside the body. Roughly one in six couples worldwide deal with infertility, and both male and female factors contribute about equally to that number.¹ The path any given person takes through fertility care depends on what the diagnostic workup reveals, how old they are, and how long they have been trying.

How Doctors Figure Out What Is Going On

Before any treatment starts, the goal is to identify what is standing in the way of conception. For women, this usually means blood tests to measure hormone levels, imaging of the uterus and fallopian tubes, and sometimes a look at the ovaries via ultrasound. One of the most telling markers is anti-Müllerian hormone, or AMH. A blood draw for AMH gives doctors a snapshot of how many developing follicles remain in the ovaries, which reflects the broader pool of eggs a woman has left.² AMH levels drop as a woman ages, and follicle-stimulating hormone (FSH) tends to rise in the opposite direction.³ Together, these numbers help clinicians estimate ovarian reserve and decide how aggressively treatment needs to proceed.

For men, a semen analysis is the cornerstone test. It measures sperm count, motility, and shape. When sperm parameters are severely abnormal, genetic testing may follow, because roughly half of all infertility cases across both sexes trace back to a genetic cause.¹ Structural issues in either partner, like blocked fallopian tubes or varicoceles, are also evaluated through imaging or minor procedures. The entire workup is meant to sort couples into categories so that the simplest effective treatment can be tried first.

First-Line Treatments Before IVF

Not everyone needs to go straight to a laboratory. For women who are not ovulating regularly, the first step is usually an oral medication that nudges the ovaries into releasing an egg. Clomiphene citrate has been the default choice for decades. In the last ten to fifteen years, letrozole, originally developed as a breast-cancer drug, has emerged as an alternative. Research confirms that letrozole plays a clear role for women who do not respond to clomiphene.⁴ Both medications are taken for a few days early in the menstrual cycle, and ovulation is then tracked with ultrasound and sometimes a blood test to confirm timing.

If ovulation is happening but pregnancy still is not, intrauterine insemination (IUI) is often the next step. In IUI, a processed sperm sample is placed directly inside the uterus with a thin catheter, bypassing the cervix and shortening the distance sperm need to travel. It works best when the fallopian tubes are open, and it is commonly used for mild male-factor problems, unexplained infertility, and cervical-factor issues. Pregnancy rates per IUI cycle land between about 10 and 20 percent, depending on the underlying diagnosis.⁵ IUI is far less expensive and less invasive than IVF, which is why it typically gets a few attempts before anyone moves on to more intensive options.

How IVF Actually Works, Step by Step

In vitro fertilization is a multi-stage process that unfolds over several weeks. It begins with controlled ovarian stimulation: injectable hormones are given daily to push the ovaries to develop multiple egg-containing follicles at once instead of the usual single one. Several stimulation protocols exist, including the agonist long protocol, the antagonist protocol, and minimal stimulation approaches. Antagonist and minimal protocols involve shorter treatment duration and fewer injections, while the long protocol tends to produce more follicles and has historically been associated with higher pregnancy rates.⁶ The choice depends on a woman’s age, ovarian reserve, and risk profile.

Once the follicles reach the right size, a trigger shot (most commonly human chorionic gonadotropin, or hCG) tells the eggs to complete their final maturation. About 36 hours later, the eggs are retrieved. This is done under light sedation: a thin needle is guided through the vaginal wall into each ovary using real-time ultrasound, and gentle suction draws the fluid and eggs out of the follicles.⁷ Simple aspiration without flushing the follicles afterward produces comparable egg-recovery rates while keeping the procedure shorter and reducing the sedation needed.⁸ The whole retrieval takes about 15 to 30 minutes, and most people go home the same day.

After retrieval, the eggs are taken to the embryology lab. In conventional IVF, eggs and sperm are placed together in a dish and fertilization happens on its own. In intracytoplasmic sperm injection (ICSI), a single sperm is injected directly into each mature egg. ICSI was originally developed for severe male-factor infertility, but its use has expanded well beyond that indication.⁹ When there is no male-factor problem, the two methods produce similar live-birth rates. A large study of over 18,000 patients found no meaningful difference in cumulative live-birth rates between ICSI and conventional IVF after adjusting for other variables. ICSI did, however, have a lower rate of total fertilization failure, about 1 percent versus 4 percent with conventional IVF.¹⁰ So ICSI can serve as insurance against the small risk that none of the eggs fertilize, even when sperm counts are normal.

From Fertilized Egg to Transferable Embryo

Once fertilization occurs, embryos are cultured in the lab for several days. They can be transferred at the cleavage stage (day 2 or 3, when they have about six to eight cells) or grown to the blastocyst stage (day 5 or 6, when they have over 100 cells and have begun to differentiate into the structures that will become the placenta and the fetus). Not every fertilized egg makes it that far. Modeling data suggest that while about 92 percent of fertilized eggs survive to cleavage stage, only around 59 percent reach blastocyst stage for a 35-year-old woman, dropping to roughly 50 percent by age 40.¹¹ The tradeoff is that blastocysts that do survive tend to be higher quality and more likely to implant.

Embryologists grade embryos under the microscope based on cell number, symmetry, and the amount of fragmentation. Research on thousands of cleavage-stage embryos has confirmed that those with eight evenly sized cells and less than 10 percent fragmentation by day 3 have the highest rates of developing into blastocysts.¹² Many clinics today favor growing embryos to the blastocyst stage when possible, because the extra days of culture serve as a natural selection process, letting embryologists pick the strongest candidates for transfer.

Fresh Versus Frozen Embryo Transfer

After culture, embryos are either transferred into the uterus right away (a “fresh” transfer) or frozen for a later cycle. The freezing question has become one of the bigger shifts in IVF practice over the past decade. A meta-analysis of randomized trials found that frozen embryo transfer (FET) was associated with higher live-birth and clinical-pregnancy rates compared with fresh transfer, along with a lower miscarriage rate and a dramatically lower risk of ovarian hyperstimulation syndrome.¹³ Separate observational data have shown the same pattern, with fertility achieved in about 29 percent of FET patients versus 19 percent with fresh transfer in one large retrospective study.¹⁴

Why the difference? Part of the explanation is biological. During the stimulation phase that precedes egg retrieval, the uterine lining is exposed to supraphysiological hormone levels that can make it less receptive to an embryo. Fresh transfer cycles show a markedly higher concentration of certain immune cells in the endometrium compared with frozen cycles, suggesting the lining’s environment is more disrupted immediately after stimulation.¹⁵ Freezing and transferring later gives the uterus time to reset. Modern vitrification, which flash-freezes embryos into a glass-like state without forming ice crystals, has made this approach practical. The technique uses high concentrations of cryoprotectants and ultra-rapid cooling rates to preserve embryos with minimal damage.

Genetic Testing of Embryos

Preimplantation genetic testing (PGT) allows clinicians to screen embryos for chromosomal abnormalities before transfer. The most common form, PGT-A (for aneuploidy), involves removing a few cells from the outer shell of a blastocyst and analyzing their chromosomes. The rationale is straightforward: transferring embryos with the correct number of chromosomes reduces miscarriage risk, shortens the time to a successful pregnancy, and greatly lowers the chance of transferring multiple embryos at once.¹⁶

The biopsy itself is invasive, though, and there has been concern about whether removing cells could harm the embryo. Non-invasive alternatives are under active development. Researchers are exploring the use of DNA shed into the fluid inside the blastocyst cavity and into the culture media the embryo sits in, which can be collected without touching the embryo at all. Early results suggest these methods can detect chromosomal abnormalities with reasonable accuracy.¹⁷ The technology is not yet mature enough to replace biopsy-based testing in most clinics, but it signals where the field is headed.

How Age Shapes Success Rates

Age is the single most powerful predictor of IVF success when a woman is using her own eggs. Each additional year past 30 is associated with roughly an 11 percent reduction in the chance of getting pregnant per cycle, and about a 13 percent drop in the chance of a live delivery.¹⁸ That decline accelerates sharply in the early 40s. At ages 43 and 44, live-birth rates per started cycle fall to around 5 percent, and in women 45 and older, clinical pregnancies using their own eggs are essentially nonexistent in published data.¹⁹ These numbers are not about overall health or fitness; they reflect the rising rate of chromosomal errors in aging eggs, which leads to both lower fertilization and higher miscarriage.

Donor eggs from a younger woman bypass this problem entirely, which is why egg donation is one of the most effective options for women over 40. When a 44-year-old uses eggs from a donor in her 20s, her success rates approximate those of the donor’s age group rather than her own. The same principle applies to embryos that were frozen at a younger age: their “clock” stopped at the point of freezing.

Complications and Safety

The most talked-about risk of IVF is ovarian hyperstimulation syndrome (OHSS). The stimulation drugs push the ovaries hard, and in some women, the ovaries overreact. The underlying problem is a surge in vascular endothelial growth factor (VEGF), a protein that increases the permeability of blood vessels. Fluid leaks out of the bloodstream into the abdomen and sometimes the lungs, causing bloating, pain, and in severe cases dangerous shifts in blood pressure and kidney function.²⁰

OHSS is largely preventable with modern protocols. Strategies include better identification of at-risk patients before treatment starts, using lower doses of the trigger shot, substituting alternative trigger medications like a GnRH agonist instead of hCG in antagonist cycles, and freezing all embryos to avoid fresh transfer when risk is high.²¹ The shift toward frozen-embryo-transfer-only cycles, discussed earlier, has had the added benefit of dramatically reducing OHSS rates at many clinics.

Third-Party Reproduction and Special Immune Considerations

Some people need eggs, sperm, or a uterus from someone else. Egg donation, sperm donation, and gestational surrogacy are all well-established pathways. But carrying an embryo that shares none of your DNA introduces a biological wrinkle that often goes unmentioned. Research has found that when a woman gestates a genetically unrelated embryo, she faces a higher risk of preeclampsia and other pregnancy complications, even after accounting for age, IVF itself, and multiple pregnancies. This elevated risk appears even in healthy, fertile surrogates carrying a single embryo made from donated eggs.²² The likely explanation is immunological: our reproductive systems evolved to tolerate embryos that are 50 percent genetically related, and a fully unrelated embryo presents a more intense immune challenge to the uterine environment. The risk appears to decrease when there is some genetic overlap, such as when a sister donates the eggs.

Long-Term Health of Children Conceived Through IVF

Parents understandably want to know whether IVF children develop differently from those conceived naturally. The honest answer is nuanced. In the short term, IVF pregnancies do carry a somewhat higher rate of preterm birth, low birth weight (particularly after fresh transfer), and birth defects compared with spontaneous conceptions.²³ Frozen transfer flips part of the pattern, with those babies tending to be slightly larger at birth. There is also growing evidence that IVF-conceived children may show subtle differences in blood pressure and cardiovascular function. Epigenetic changes, alterations in how genes are switched on and off without changing the DNA sequence itself, have been observed in IVF offspring and are one proposed mechanism.²⁴

A key question researchers are still untangling is how much of this is caused by the IVF process itself versus the underlying infertility that led to treatment in the first place. Overall, though, evidence about the longer-term health of children conceived through IVF is described as reassuring. The vast majority develop normally through childhood and adolescence.²⁵ The field is still young enough that we are only now seeing the first large cohorts of IVF-conceived adults entering middle age, so some questions about very long-term cardiovascular and metabolic health remain open.

The Emotional Side of Fertility Treatment

The physical mechanics of treatment get most of the attention, but the psychological burden is the reason many people stop. In one questionnaire study, lack of success and psychological stress together drove more treatment discontinuation than financial barriers. About 36 percent of couples cited psychological stress as a factor in their decision to stop, and the overlap between stress and perceived lack of success was striking, with both factors reinforcing each other as cycles accumulated.²⁶ Even among patients with insurance coverage, psychological factors play a significant role in dropping out before exhausting all available cycles.²⁷ This suggests that access to mental-health support during treatment is not a luxury but something that materially affects whether people achieve a pregnancy.

Who Gets Access and Who Does Not

Fertility treatment is expensive, and who can afford it shapes the demographics of IVF clinics. In the United States, the majority of women receiving treatment have at least a bachelor’s degree, and over 80 percent have household incomes above $100,000 a year.²⁸ Black and Hispanic women travel about twice as far to reach a fertility clinic compared with white and Asian women, and they are significantly more likely to report that income is a barrier. Black women are also far more likely to perceive race itself as a barrier to receiving care.

Insurance coverage is a major driver of these gaps. Only 15 states require some private insurers to cover any fertility treatment, and significant gaps persist even in those states. Only one state Medicaid program covers fertility treatment at all, and none covers IUI or IVF.²⁹ LGBTQ individuals face an additional hurdle: insurance definitions of “infertility” often require a documented period of unprotected intercourse that cannot apply to same-sex couples, effectively excluding them from covered services.

Emerging Tools on the Horizon

Two areas of innovation are worth watching. The first is microfluidic sperm selection, which uses tiny channels that mimic the anatomy of the female reproductive tract to sort sperm by motility and DNA integrity without centrifugation. Lab studies show the devices can produce sperm with less DNA damage, and some clinical reports have suggested improved pregnancy rates.³⁰ However, a systematic review and meta-analysis found no significant evidence yet that microfluidic selection actually improves clinical outcomes compared with standard sperm-preparation methods.³¹ Promising concept, not yet proven in large trials.

The second frontier is artificial intelligence for embryo selection. Traditionally, embryologists evaluate embryos under a microscope and make a judgment call about which ones look most promising. AI models trained on images, time-lapse video, and clinical data have shown median accuracy rates in the low-to-mid 80s for predicting clinical pregnancy when combining visual and clinical inputs, compared with roughly 50 percent accuracy for embryologists making the same predictions.³² That gap is striking, though it is worth noting that these comparisons involve AI models tested under controlled research conditions and the accuracy ranges are wide. Real-world validation across diverse patient populations is still ongoing. If AI-guided selection holds up, it could reduce the number of failed transfers and shorten the time to pregnancy for many patients.